SciELO - Scientific Electronic Library Online

 
vol.21 número4Epidemiology of aquatic animal poisonings reported to a Colombian toxicology control centerNeuroscience and exercise: an indicator of health and learning in the educational context índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista de Salud Pública

versão impressa ISSN 0124-0064

Resumo

ARANDA, Monica B.  e  SABALETTE, Karina B.. Biological cancer therapies: an approach towards accessibility. Rev. salud pública [online]. 2019, vol.21, n.4, pp.462-468.  Epub 11-Ago-2020. ISSN 0124-0064.  https://doi.org/10.15446/rsap.v21n4.73686.

Monoclonal antibodies are a useful tool for laboratory diagnosis and an instrument used in the treatment of various diseases and represent one of the most important groups of new drugs for the treatment of cancer. The revolution in the world occured in 1975 when Milstein and Köhler discovered monoclonal antibodies in Cambridge.

Objective

To review the use of monoclonal antibodies in medicine and in the treatment of cancer. To provide a generalized vision of the concept of monoclonal antibody to explain its therapeutic applicability, and to approach an economic, health-care approach to obtaining and accessing new therapies.

Method

In the characterization of the research phenomenon, the descriptive study, the collection of documentary data and the correlation between the different sources were used.

Discussion

However, the costs for both the patient and the public health systems are still high, and the cost-effectiveness assessment must be optimized so that cost-effectiveness and access to time for patients can be compatible. And the challenge of developing new mAbs aimed at new targets, improving the safety profile, avoiding, or reducing adverse immune reactions and achieving lower production costs through improvements in biotechnology, is left open.

Palavras-chave : Biological therapy; antibodies; monoclonal; biosimilar pharmaceuticals (source: MeSH, NLM).

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )